Carotid body tumor encounters over a two-decade period in an academic hospital. Issue 41 (14th October 2022)

• Record Type: Journal Article
• Authors: Altoijry, Abdulmajeed; Alghofili, Hesham; Iqbal, Kaisor; Altuwaijri, Talal; Aljabri, Badr; Al-Salman, Mussaad
• Is Part Of: Medicine. Volume 101:Issue 41(2022)
• Page Start: e31110
• Publication Date: 2022-10-14
• Subjects: carotid body tumor -- CBT -- chemodectome -- paraganglioma; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000031110
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Carotid body tumors (CBTs) are rare and mostly benign. Research outcomes usually arise from single-center data. We conducted this study to present the characteristics and outcomes of patients who underwent surgical resection of CBT at our hospital over the past 20 years. In this retrospective review, the records of CBTs in our hospital were reviewed between 1998 and 2021. All patients who underwent CBT resection were included. The follow-up period was 12 months. A total of 44 CBTs were treated in our hospital. The male-to-female ratio was 1:2.4. Only 4.5% of patients had Shamblin I tumors. Patients with Shamblin II and III tumors were 56.8% and 38.6%, respectively. Duplex scan was used to diagnose CBT in all of the patients. The majority of our patients (97.7%) did not receive any preoperative embolization despite an average tumor size of 4.9 cm. Cranial nerve injuries were observed in 29.5% of cases. Meanwhile, stroke was reported in only two cases (4.5%). No deaths were encountered. Surgery is the definitive treatment for CBT. Size and local extension appear to be the main reasons for adverse events rather than surgical techniques. Our results are consistent with those of previously published studies. Good outcomes are expected in high-volume centers with appropriate preoperative imaging.